Date: 2017-01-05
Type of information: Series B financing round
Company: Nerre Therapeutics (UK)
Investors: Fountain Healthcare Partners (Ireland) Forbion Capital Partners (The Netherlands) OrbiMed (USA - NY) Advent Life Sciences (UK) Novo A/S (Sweden)
Amount: £23 million
Funding type: series B financing round
Planned used: NeRRe Therapeutics is a clinical-stage company developing a unique portfolio of neurokinin (NK) receptor antagonists for the treatment of common, chronic and debilitating conditions caused by neuronal hypersensitivity. The funds will be used by NeRRe to generate Phase 2 data on orvepitant, its lead oral NK-1 antagonist candidate as a potential new treatment for a common, chronic respiratory condition; and to advance NT-814, a dual NK-1,3 antagonist, into Phase 2 trials as a potential non-hormonal treatment of distressing post-menopausal vasomotor symptoms. The company was founded in 2012 as a spin out from GSK, which transferred its NK antagonist portfolio, including clinical data, toxicity, safety and formulation packages, and all associated IP to NeRRe. NeRRe is led by Dr Mary Kerr (CEO), formerly SVP and Global Franchise lead at GSK and Dr Mike Trower (Co-founder, CSO/COO), formerly VP & Head of the External Drug Discovery Group in the Neurosciences CEDD at GSK.
Others:
Therapeutic area:
